Normosang (Human Hemin)

Human hemin supplies external heme, which binds to regulatory sites that suppress the enzyme aminolevulinic acid synthase (ALAS1). By down‑regulating ALAS1, the production of neurotoxic precursors such as aminolevulinic acid and porphobilinogen is reduced, mitigating the biochemical cascade that drives acute porphyria symptoms.

The specific dose of Normosang is determined by the prescribing clinician based on the severity of the porphyria attack, patient weight, and clinical response. Dosing regimens are individualized and should follow the guidance provided in the product’s prescribing information.

Safety data for Normosang in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Normosang, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where applicable) and import documentation.

Normosang (human hemin) and heme arginate (Panhematin) are the two main heme‑based treatments for acute porphyria. Both act by supplying exogenous heme to suppress ALAS1, but they differ in formulation, dosing schedules, and regulatory approvals. Choice of therapy depends on local availability, clinician preference, and specific patient factors.

Normosang should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The lyophilized powder should be reconstituted with the appropriate diluent immediately before intravenous administration and used within the time frame specified in the product label.

Normosang is supplied as a lyophilized powder for solution for injection. After reconstitution with sterile diluent, the solution is administered intravenously over a prescribed period, typically as a slow infusion under clinical supervision to monitor for infusion‑related reactions.

The most serious adverse events linked to Normosang include anaphylactic reactions, hemolysis (especially in patients with G6PD deficiency), acute renal failure, thrombophlebitis, and coagulopathy. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Normosang is contraindicated in patients with known hypersensitivity to human hemin or any of the excipients in the formulation. Caution is advised for individuals with G6PD deficiency, severe renal impairment, or uncontrolled hypertension, and it should be avoided in patients where the risks outweigh the therapeutic benefits.